MedTrace Logo

Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults

NCT01250795 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2016-05-12

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, immunogenicity,and tolerability of a H5N1 Vaccine in healthy adults.

Conditions

  • Healthy

Interventions

BIOLOGICAL

HAI-05 Influenza Vaccine

injection, vaccine, twice every 3 weeks

OTHER

Saline

Sponsors & Collaborators

  • Fraunhofer, Center for Molecular Biotechnology

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01250795 on ClinicalTrials.gov